The Kidney Disease Improving Global Outcomes (KDIGO) 2017 guideline on the management of CKD-MBD recommend that in patients with CKD G3a–G5D, treatment of CKD-MBD should be based on serial assessments of calcium, phosphate, and PTH levels, considered together [85]. The gene discussed is PTH; the disease is Marchiafava-Bignami disease.